Showing 2871-2880 of 5646 results for "".
- Excel-Lens Announces CE Mark Approval for CAPSULaser Selective Laser Capsulotomy (SLC) Devicehttps://modernod.com/news/excel-lens-announces-ce-mark-approval-for-capsulaser-selective-laser-capsulotomy-slc-device/2479872/Excel-Lens announced the CE mark approval of CAPSULaser, a selective laser that creates a capsulotomy during cataract surgery in just over a second. The laser energy is delivered in a continuous manner rather than a pulsed beam which can create tissue bridges. In clinical studies, CAPSULas
- LumiThera to Debut Valeda Light Delivery System at EURETINAhttps://modernod.com/news/lumithera-to-debut-valeda-light-delivery-system-at-euretina/2479887/LumiThera announced that it will debut the Valeda Light Delivery System for the treatment of dry AMD in the exhibition hall at the EURETINA meeting in Vienna. It will also host a symposium on photobiomodulation (PBM) technology entitled, “Photobiomodulation: An Innovative, Mitochondria-targ
- Clearside Biomedical to Present Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitishttps://modernod.com/news/clearside-biomedical-to-present-pivotal-phase-3-peachtree-clinical-trial-in-macular-edema-associated-with-non-infectious-uveitis/2479896/Clearside Biomedical announced that data from PEACHTREE, its pivotal phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Rahul N. Khurana, MD, an investigator for PEACHTREE, Partner at Northern California Retina Vitreo
- Alcon to Move Headquarters from Texas to Switzerland Following Proposed Spinoff From Novartishttps://modernod.com/news/alcon-to-move-headquarters-from-texas-to-switzerland-following-proposed-spinoff-from-novartis/2479901/Alcon announced plans to locate its future global headquarters in Geneva, Switzerland, following completion of its proposed spinoff from Novartis, which is expected to be completed in the first half of 2019. Alcon’s new global headquarters in Geneva will be the primary location for A
- MeiraGTx Announces AAV-CNGA3 Granted Rare Pediatric Disease Designation by the U.S. FDA for the Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cnga3-granted-rare-pediatric-disease-designation-by-the-u-s-fda-for-the-treatment-of-achromatopsia/2479906/Gene therapy company MeiraGTx Holdings announced that the FDA has granted rare pediatric disease designation to the company’s gene therapy product candidate AAV-CNGA3 for the treatment of patients with achromatopsia (ACHM) due to mutations in the CNGA3 gene. ACHM is an inherited r
- UK Calls on Drugmakers to Stockpile 6-Week Supply of Medicines to Cope With “No Deal” Brexithttps://modernod.com/news/uk-calls-on-drugmakers-to-stockpile-6-week-supply-of-medicines-to-cope-with-no-deal-brexit/2479911/The UK’s Department of Health and Social Care has asked pharmaceutical companies that supply drugs to NHS patients to “ensure they have a minimum of six weeks additional supply” of medicines, over and above their usual buffer stocks, in case imports from the EU are disrupted in
- Devices to Expand Role of Surgery in Glaucoma Treatmenthttps://modernod.com/news/devices-to-expand-role-of-surgery-in-glaucoma-treatment/2479914/The glaucoma surgical device market is expected to grow at a rate of nearly 23 percent over the next 5 years, according to a Market Scope report. The market is expected to grow to nearly $1.7 billion by 2023, up from a small base of just under $634 million in 2018. Minimally invasive glauc
- Open-Angle Glaucoma in One Eye Likely to Develop in the Otherhttps://modernod.com/news/open-angle-glaucoma-in-one-eye-likely-to-develop-in-the-other/2479915/Patients with open-angle glaucoma in one eye are at increased risk for developing glaucoma in the second eye, researchers report, according to Reuters Health. “Among patients with newly diagnosed open-angle glaucoma, almost ha
- MeiraGTx Announces AAV-CNGB3 Granted Fast Track Designation by FDA for Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cngb3-granted-fast-track-designation-by-fda-for-treatment-of-achromatopsia/2479927/MeiraGTx Holdings announced that the FDA has granted Fast Track designation for its AAV-CNGB3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the CNGB3 gene. ACHM is an inherited retinal disease that severely limits a person’s sight
- Web Vision Technologies Receives Grants to Develop Vision Testing Devices for NASAhttps://modernod.com/news/web-vision-technologies-receives-grants-to-develop-vision-testing-devices-for-nasa/2479953/Web Vision Technologies was recently awarded two grants from Translational Research Institute for Space Health (TRISH) at Baylor College of Medicine to develop vision-testing devices for the National Aeronautical Space Administration (NASA) to be used on the International Space Station (ISS). The